>>DUBLIN, Calif., Nov 21 (Reuters) - Pharmaceuticals company SuperGen Inc. (NasdaqNM:SUPG - news) said on Wednesday that U.S. regulators approved its anti-cancer drug daunorubicin.
The firm, which is partly owned by Abbott Laboratories Inc.(NYSE:ABT - news), said the U.S. Food and Drug Administration approved daunorubicin as a treatment for a variety of acute leukemias.
In addition to daunorubicin, SuperGen's also markets Nipent to treat hairy cell leukemia and is in clinical development for a variety of other leukemias, graft-versus-host disease and bone marrow transplantation.
It also has an experimental drug called Rubitecan, which is in clinical development for treatment of pancreatic cancer, as well as ovarian, prostate, lung and stomach cancers.
Shares of SuperGen traded up 28 cents, or 2 percent to $13.25 in early activity on the $13.30.<<
snip
Cheers, Tuck |
